We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Shares Quality Considerations for Ophthalmic Drugs in Draft Guidance
FDA Shares Quality Considerations for Ophthalmic Drugs in Draft Guidance
The FDA’s newest draft guidance discusses quality considerations for ophthalmic drugs, including ways to assess impurities, evaluate visible contaminants, design containers and conduct stability studies.